series-b
Stage
1
Investors
About
Vittoria Biotherapeutics develops next-generation autologous CAR T-cell therapies using its proprietary SENZA5 platform to treat oncology and immunology diseases, currently with multiple clinical trials underway.
Explore Vittoria Biotherapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.